title: Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress.
abstract: Although doxorubicin is an effective antitumor agent, the serious cardiotoxicity mediated by the production of reactive oxygen species has remained a considerable clinical problem. In China, salvianolic acids has been widely used for cardioprotection. To test whether salvianolic acids holds the potential to be protective against cardiotoxicity of doxorubicin, we created an acute cardiac injury mice model. Therapeutic treatment with salvianolic acids (40 mg/kg for 3 connective days) significantly reduced doxorubicin-induced (15 mg/kg) toxicity, including elevation of body weight and heart weight/tibia length ratio, decrease of creatine kinase, improvement of electrocardiography and heart vacuolation. Furthermore, the antioxidative effects of salvianolic acids were verified by oxygen radicals absorbance capacities assay in vitro and malondialdehyde detection in vivo, suggesting one possible mechanism of salvianolic acids on cardioprotection through blocking oxidative stress.
authors.affiliation: Shanghai Research Center for Modernization of Traditional Chinese Medicine, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China. baohong_jiang@yahoo.com.cn
authors.forename: Baohong
authors.initials: B
authors.lastname: Jiang
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Wanying
authors.initials: W
authors.lastname: Wu
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.forename: Junchen
authors.initials: J
authors.lastname: Wang
authors.forename: De-an
authors.initials: DA
authors.lastname: Guo
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D001572:Benzofurans / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002109:Caffeic Acids / Q000494:pharmacology*; D002316:Cardiotonic Agents; D003402:Creatine Kinase / Q000378:metabolism; D004317:Doxorubicin / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D004562:Electrocardiography / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D007773:Lactates / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D009206:Myocardium / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000378:metabolism; D016707:Tissue Fixation; D053630:Depsides
chemical_list: D000903:Antibiotics, Antineoplastic; D001572:Benzofurans; D002109:Caffeic Acids; D002316:Cardiotonic Agents; D003402:Creatine Kinase; D004317:Doxorubicin; D007773:Lactates; D008315:Malondialdehyde; D017382:Reactive Oxygen Species; C066201:salvianolic acid A; C076944:salvianolic acid B; D053630:Depsides